

1 **Impact of body mass index on 5-year survival rates in patients undergoing allogeneic**

2 **hematopoietic stem cell transplantation**

3

4 **Short title**

5 Body weight and allo-HSCT outcomes

6

7 Takashi Aoyama<sup>1</sup>, Akifumi Notsu<sup>2</sup>, Koki Ichimaru<sup>3</sup>, Masanori Tsuji<sup>3</sup>, Kanako Yoshitsugu<sup>3</sup>,

8 Masafumi Fukaya<sup>3</sup>, Terukazu Enami<sup>3</sup>, Takashi Ikeda<sup>3</sup>

9

10 <sup>1</sup>Dietary Department, Shizuoka Cancer Center, Shizuoka, Japan

11 <sup>2</sup>Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan

12 <sup>3</sup>Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka,

13 Japan

14

15 **Corresponding author**

16 Takashi Aoyama

17 Dietary Department, Shizuoka Cancer Center

18 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan

19 Tel: +81-55-989-5222

20 Fax: +81-55-989-5634

21 E-mail: t.aoyama@scchr.jp

22 **Funding**

23 None.

24 **Abstract**

25 ***Background***

26 The association between cancer survival and body mass index (BMI) has been elucidated. However,

27 the impact of patients' baseline characteristics on allogeneic hematopoietic stem cell transplantation

28 (allo-HSCT) outcomes remains unclear.

29 ***Objectives***

30 To examine the baseline clinical factors associated with 5-year survival rates in patients undergoing

31 allo-HSCT.

32 ***Study design***

33 This was a retrospective exploratory observational study. Patients (n=113, average age: 55 years; 52  
34 women) who underwent allo-HSCT at the Division of Hematology and Stem Cell Transplantation,  
35 Shizuoka Cancer Center, between January 2008 and March 2015 were included in this study.

### 36 ***Results***

37 The 5-year survival rate (65%) was associated with the baseline geriatric nutritional risk index  
38 (GNRI; odds ratio [OR]=1.20, 95% confidence interval [CI]: 1.03–1.36, P <0.01) and the BMI  
39 (OR=1.06, 95% CI: 1.02–1.12, P <0.01). The cut-off values for BMI and GNRI were 20.5 kg/m<sup>2</sup> and  
40 101 points, respectively (area under the curve, 0.65017 and 0.67637, respectively). The 5-year  
41 survival rate was poorer for patients with sarcopenia (41.5%) than for those without sarcopenia prior

42 to allo-HSCT (p=0.05).

43 ***Conclusions***

44 BMI and GNRI values before allo-HCST pre-treatment were independent predictors of the 5-year

45 survival rates. Patients undergoing allo-HSCT may require nutritional interventions during

46 pre-treatment to reduce the risk of sarcopenia, which affects their survival rates.

47

48 **Keywords**

49 allogeneic hematopoietic stem cell transplantation, body mass index, geriatric nutritional risk index,

50 sarcopenia

51

52 **Introduction**

53 A cohort study found that standardized body mass index (BMI) is associated with cancer survival [1].

54 In Japan, the 5-year survival rates (2009–2011) associated with leukemia, multiple myelomas, and

55 malignant lymphomas have been reported to be 44.0%, 42.8%, and 67.5%, respectively [2].

56 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used to achieve remission in cases

57 of hematopoietic tumors. Body weight loss has been associated with allo-HSCT outcomes [3];

58 however, this association has not been examined in a multivariate study. Furthermore, no previous

59 study has examined the impact of nutritional assessment on allo-HSCT outcomes. At the Shizuoka

60 Cancer Center (SCC) Division of Hematology and Stem Cell Transplantation, patients are provided  
61 with a nutritional intervention using a nutritional pathway [4]; however, the relationships between the  
62 patients' clinical characteristics and outcomes have not yet been examined. The aim of this study was  
63 to examine the impact of the patients' baseline clinical characteristics on allo-HSCT outcomes and to  
64 examine the role of nutritional interventions in this context.

65

## 66 **Materials and Methods**

67 This retrospective, exploratory, observational study included 120 patients (age: 16–70 years) who  
68 underwent allo-HSCT (transplantation day: day 0) and for whom a nutritional pathway intervention



69 was recommended at the SCC Division of Hematology and Stem Cell Transplantation between  
70 January 2008 and March 2015. Patients were excluded from this study if data on their clinical  
71 characteristics were lacking. Allo-HSCT pre-treatments included myeloablative conditioning (MAC),  
72 reduced-intensity conditioning (RIC), and human leukocyte antigen (HLA)-matching. Transplantation  
73 types included unrelated donor bone marrow transplantation (UR-BMT), cord blood transplantation  
74 (CBT), and allogeneic peripheral blood stem cell transplantation (allo-PBSCT) [5].  
75 Patients were evaluated before undergoing pre-treatment (T1) and 5 years after receiving their  
76 transplant (T2). Remission status at T1 was not evaluated for patients with myelodysplastic  
77 syndromes [5] for which the remission status could not be determined. Data were collected on the

78 following variables: 5-year survival rates (using day 0 as the starting point); pre-treatment type (MAC,  
79 RIC, and HLA-matching) and transplantation type (UR-BMT, CBT, and allo-PBSCT) and associated  
80 survival outcomes; baseline age; BMI; skeletal muscle index (SMI, assessed with a bioelectrical  
81 impedance analyzer [BIA: In Body S20®]) [6,7]; skeletal muscle mass (SMM) [8]; fat mass (FM);  
82 phase angle [9]; geriatric nutritional risk index (GNRI) [10] values (which were compared between  
83 the treatment and transplantation types); hematopoietic cell transplantation-specific comorbidity index  
84 (HCT-CI) [11]; and incidence of graft-versus-host disease (GVHD; grade  $\geq 1$ ). The 5-year survival  
85 rates were the outcomes of interest. The cut-off values of BMI associated with the outcomes were  
86 estimated. The BMI was divided into the following 3 categories: underweight ( $<18.5 \text{ kg/m}^2$ ), normal

87 weight (18.5–24.9 kg/m<sup>2</sup>), and overweight ( $\geq 25.0$  kg/m<sup>2</sup>) [12]; the 5-year survival rates were

88 compared among these categories. SMI was used to diagnose sarcopenia at T1 (women:  $< 5.7$  kg/m<sup>2</sup>,

89 men:  $< 7.0$  kg/m<sup>2</sup>) [13]; the survival rates were compared between patients with and without

90 sarcopenia. The association between GNRI was calculated as follows:  $(14.89 \times \text{serum albumin level})$

91  $+ (41.7 \times [\text{body weight/ideal body weight}])$ . The association between GNRI at T1 and survival was

92 evaluated; the cut-off value associated with survival outcomes was estimated. Survival rates were

93 compared between groups defined on the basis of a cut-off value of  $< 99$  points at T1.

94 Measurements with the InBody S20® device were taken 2 h after breakfast (from 10:00 a.m. to 12:00

95 noon). We set the reference extracellular fluid-to-total body fluid ratio as 0.35 and the extracellular

96 water-to-total body water ratio as 0.40. We defined the upper limits of the extracellular fluid-to-total  
97 body fluid ratio and the extracellular water-to-body water ratio (indicating mild edema) as 0.35–0.38  
98 and 0.40–0.43, respectively. If edema was noted, the measurements were obtained again to control for  
99 the impact of edema. All variables were measured using a high-precision body composition analyzer  
100 (InBody S20®); the value frequencies were calculated [14]. Data on the HCT-CI, GVHD, and HLA  
101 matching were examined using the Transplant Registry Unified Management Program [15].

102

### 103 *Statistical analyses*

104 Normality of distribution was verified using the Shapiro–Wilk test, and all variables were expressed

105 as median values (minimum–maximum). Univariate logistic regression analysis was used to assess the

106 relationship between the clinical characteristics at T1 and the 5-year survival and GVHD rates. The

107 associations of age with SMI and BMI were assessed using the Pearson’s product moment correlation.

108 The associations of BMI with pre-treatment methods and transplantation types were assessed with an

109 analysis of variance (ANOVA). Cut-off values for the associated factors were calculated using the

110 receiver operating characteristic curve. Differences in the pre-treatment method, HLA, and

111 transplantation types between surviving and non-surviving patients were examined using the

112 chi-square test and the Steel–Dwass test. A survival curve was created using the Kaplan–Meier

113 method, and associations between the survival rate, BMI (3 categories), SMI (sarcopenia), and GNRI

114 were assessed using the log-rank test. All statistical analyses were performed using JMP (version

115 12.0®; SAS Institute, USA) and R (version 3.6.3; R Core Team [2020], [www.r-project.org](http://www.r-project.org)).

116 Two-sided p-values of <0.05 were considered statistically significant.

117

118 ***Ethical considerations***

119 This clinical study was performed in accordance with the declaration of Helsinki and approved by the

120 Shizuoka Cancer Center institutional review board (SCC IRB; approval number: J2021-49). Verbal

121 consent was obtained from the patients in accordance with the IRB's recommendations.

122

123 **Results**

124 A total of 113 patients were included in the analysis. Seven patients were excluded due to missing

125 baseline data. The performance status (PS) at T1 was 0 in all cases. The patients' median age was 55

126 years (range, 17–70 years;  $p < 0.01$  by the Shapiro–Wilk test); the mean ages for women and men were

127 53 years (17–69 years) and 57 years (17–70 years), respectively ( $p < 0.01$ ). The patients' characteristics

128 are presented in Table 1.

129 Table 1. Patients' background characteristics

N

---

Cases (female/male)

113 (51/62)

---

Disease

36

AML

24

ML

23

MDS

18

ALL

4

MM

3

CLL

3

ATL

2

AA



---

Conditioning regimen

85

MAC

51

BU (> 6.4 mg/kg)

23

TBI ( $\geq$  8 Gy)

11

MEL (> 140 mg/m<sup>2</sup>)

28

RIC

18

TBI (< 8 Gy)

10

MEL ( $\leq$  140 mg/m<sup>2</sup>)

---

Transplant type

66

---

|   |       |
|---|-------|
| Unrelated bone marrow transplantation                 | 26    |
| Cord blood stem cell transplantation                  | 21    |
| Allogeneic peripheral blood stem cell transplantation |       |
| HLA: matched/mismatched                               | 56/57 |

---

|                       |          |
|-----------------------|----------|
| GVHD incidence (rate) | 93 (82%) |
| Grade 1               | 44       |
| Grade 2               | 42       |
| Grade 3               | 6        |

|         |   |
|---------|---|
| Grade 4 | 1 |
|---------|---|

---

|                        |          |
|------------------------|----------|
| HCT-C incidence (rate) | 34 (30%) |
|------------------------|----------|

|         |    |
|---------|----|
| 1 point | 18 |
|---------|----|

|         |   |
|---------|---|
| 2 point | 4 |
|---------|---|

|         |   |
|---------|---|
| 3 point | 6 |
|---------|---|

|         |   |
|---------|---|
| 4 point | 4 |
|---------|---|

|         |   |
|---------|---|
| 5 point | 1 |
|---------|---|

|         |   |
|---------|---|
| 6 point | 1 |
|---------|---|

AML: acute myelogenous leukemia, ML: malignant lymphoma, MDS:

myelodysplastic syndromes, ALL: acute lymphoid leukemia, MM: multiple

myeloma, CLL: chronic lymphatic leukemia, ATL: adult T-cell leukemia

lymphoma, AA: aplastic anemia, MAC: myeloablative conditioning, BU:

busulfan, TBI: total-body irradiation, MEL: melphalan, RIC:

reduced-intensity conditioning, UR-BMT: unrelated bone marrow

transplantation, CBT: cord blood stem cell transplantation, allo-PBSCT:

allogeneic peripheral blood stem cell transplantation, HLA: human leukocyte

antigen, GVHD: graft-versus-host disease, HCT-CI: hematopoietic cell

transplant-comorbidity

130

131 The overall 5-year mortality rate was 35% (n=40, including 17 women and 23 men). The

132 non-surviving group included 16 patients with acute myelogenous leukemia (AML; 8 women, 8 men),

133 7 patients with malignant lymphoma (ML; 3 women, 4 men), 7 patients with myelodysplastic

134 syndromes (MDS; 2 women, 5 men), 6 patients with acute lymphoid leukemia (ALL; 3 women, 3

135 men), 4 patients with multiple myeloma (MM; 1 woman, 3 men), and 1 patient with chronic

136 myelogenous leukemia (CML; 1 man). The mean age of the non-surviving group was 59 years (range,

137 18–70 years). At T1, the mean ages of women and men were 54 years (30–64 years) and 61 years  
138 (18–70 years), respectively. Furthermore, the overall survival period was 322 days (range, 46–1,756  
139 days; women: 439 days [102–1,496 days], men: 273 days [46–1,756 days]). The overall 5-year  
140 survival rate was 65% (73/113; 34/51 women, 39/62 men); these included 20 (9 women, 11 men), 16  
141 (7 women, 9 men), 14 (8 women, 6 men), 15 (6 women, 9 men), 1 (0 women, 1 man), 2 (1 woman, 1  
142 man), 3 (1 woman, 2 men), and 2 (0 women, 2 men) patients diagnosed with AML, ML, MDS, ALL,  
143 MM, CML, adult T-cell leukemia (ATL), and aplastic anemia (AA), respectively.  
144 A total of 54 and 19 surviving patients underwent MAC and RIC, respectively, at a rate comparable to  
145 that observed among non-surviving cases (31 and 9, respectively;  $p=0.68$ ). Surviving and

146 non-surviving groups had comparable rates of complete and partial HLA matches (37 and 19 in the  
147 surviving and 37 and 20 in the non-surviving groups, respectively;  $p=0.90$ ). Overall, 88, 41, and 24  
148 patients received UR-BMT, CBT, and allo-PBSCT respectively; there were significant differences  
149 between the surviving group and the non-surviving group (UR-BMT: 66 vs. 22:  $p=0.23$ , CBT: 26 vs.  
150 15:  $p<0.01$ ; allo-PBSCT: 21 vs. 3:  $p<0.05$ ).

151 There was no association between age and BMI ( $r=0.04$ ,  $p=0.69$ ) or between age and SMI ( $r=0.03$ ,  
152  $p=0.76$ ) at T1. At T1, the BMI was  $21.1 \text{ kg/m}^2$  in MAC cases ( $14.1\text{--}31.0 \text{ kg/m}^2$ ;  $p=0.55$  by the  
153 Shapiro–Wilk test) and  $21.9 \text{ kg/m}^2$  in 28 RIC cases ( $17.8\text{--}29.5 \text{ kg/m}^2$ ,  $p=0.07$ ), without any  
154 significant between-group differences (ANOVA:  $p=0.06$ ). Furthermore, at T1, the BMIs were 21.5

155 kg/m<sup>2</sup> (14.1–29.3, p=0.99), 22.1 kg/m<sup>2</sup> (15.0–31.0, p=0.58), and 20.6 kg/m<sup>2</sup> (16.5–27.5, p=0.91)

156 among patients who received UR-BMT (n=66), CBT (n=26), and allo-PBSCT (n=21), respectively

157 (p=0.18).

158 Clinical characteristics associated with the onset of GVHD (grade  $\geq 1$ ) are presented in Table 2. The

159 BMI, GNRI, SMI (female), SMM (female), and FM (total only) were associated with the 5-year

160 survival rates (Fig. 1).

161 Figure 1. Odds ratios and confidence intervals associated with baseline clinical characteristics in

162 surviving and non-surviving patients

163 Table 2. Clinical indicators assessed during the nutritional evaluation



\**p*

---

|                           |                                    |       |
|---------------------------|------------------------------------|-------|
| Body weight (range) at T1 | 58.0 kg (36.2–96.5)                | 0.07  |
| female                    | 52.9 kg (36.2–76.2)                | 0.02  |
| male                      | 62.0 kg (46.3–96.5)                | <0.01 |
| IBW% (range) at T1        | 98.2% (64.1–140.9)                 | 0.59  |
| female                    | 94.2% (64.1–133.5)                 | 0.56  |
| male                      | 99.6% (74.2–140.9)                 | <0.05 |
| BMI (range) at T1         | 21.4 kg/m <sup>2</sup> (14.1–31.0) | 0.4   |
| female                    | 20.7 kg/m <sup>2</sup> (14.1–29.3) | 0.56  |

---

|                    |                                    |       |
|--------------------|------------------------------------|-------|
| male               | 21.7 kg/m <sup>2</sup> (16.3–31.0) | <0.05 |
| GNRI (range) at T1 | 102.1 (76.0–124.3)                 | 0.39  |
| female             | 103.5 (86.9–121.6)                 | 0.37  |
| male               | 100.9 (76.0–124.3)                 | 0.12  |

---

|                         |                                 |       |
|-------------------------|---------------------------------|-------|
| Engraftment day (range) | Day 18 (9–35)                   | <0.01 |
| UR-BMT                  | Day 18 (9–28)                   | <0.01 |
| CBT                     | Day 21 (13–35)                  | <0.05 |
| Allo-PBSCT              | Day 16 (11–22)                  | 0.75  |
| BIA: SMI (range) at T1  | 6.5 kg/m <sup>2</sup> (3.5–8.7) | 0.17  |

---

|                        |                                 |      |
|------------------------|---------------------------------|------|
| female                 | 5.7 kg/m <sup>2</sup> (3.5–6.5) | 0.85 |
| male                   | 7.3 kg/m <sup>2</sup> (5.3–8.7) | 0.46 |
| BIA: SMM (range) at T1 | 23.1 kg (10.8–34.5)             | 0.2  |
| female                 | 18.5 kg (10.8–31.1)             | 0.15 |
| male                   | 26.8 kg (17.0–34.5)             | 0.9  |

---

|                       |                    |       |
|-----------------------|--------------------|-------|
| BIA: FF (range) at T1 | 14.7 kg (3.7–36.5) | <0.01 |
| female                | 17.1 kg (4.7–30.0) | 0.57  |
| male                  | 13.9 kg (3.7–36.5) | <0.01 |

---

|                            |                   |       |
|----------------------------|-------------------|-------|
| BIA: ECF/TBF (range) at T1 | 0.35 (0.32–0.37)  | 0.23  |
| BIA: ECW/TBW (range) at T1 | 0.40 (0.36–0.42)  | <0.01 |
| BIA: Pa (° range) at T1    | 4.78° (2.84–6.96) | 0.48  |
| female                     | 4.65° (2.84–6.68) | 0.54  |
| male                       | 4.89° (3.28–6.96) | 0.7   |

---

IBW: ideal body weight, BMI: body mass index, GNRI: geriatric nutritional risk index, UR-BMT:

unrelated bone marrow transplantation, CBT: cord blood stem cell transplantation, Allo-PBSCT:

allogeneic peripheral blood stem cell transplant, BIA: bioelectrical impedance analysis, SMI: skeletal

muscle mass index, SMM: skeletal muscle mass, FM: fat mass, ECF: extracellular fluid, TBF: total

body fluid, ECW: extracellular water, TBW: total body water, Pa: phase angle

164

165 The BMI cut-off value associated with the 5-year survival rates was 20.5 kg/m<sup>2</sup> (Fig. 2).

166 Figure 2. Receiver operating characteristics curve for survival, depending on the baseline body mass

167 index

168 Furthermore, 14, 80, and 19 patients were underweight (<18.5 kg/m<sup>2</sup>), of normal weight (18.5–24.9

169 kg/m<sup>2</sup>), and overweight (≥25.0 kg/m<sup>2</sup>), respectively. Significant differences were observed in the

170 5-year survival rates between the underweight, normal weight, and overweight groups (Fig. 3–5). The

171 T1 SMI was indicative of sarcopenia in 47 out of 113 (41.5%) patients. There were differences in the

172 survival rates between patients with and without sarcopenia (Fig. 6).

173 Figure 3. Five-year survival rates by the body mass index category (underweight, normal weight, and

174 overweight)

175 Figure 4. Five-year survival rates by the body mass index category (overweight and underweight)

176 Figure 5. Five-year survival rates by the body mass index category (normal weight and underweight)

177 Figure 6. Five-year survival rate by the sarcopenia status (skeletal muscle index, extremity skeletal

178 muscle mass/tool<sup>2</sup>: women <5.7 kg/m<sup>2</sup>, men <7.0 kg/m<sup>2</sup>)

179 The GNRI cut-off value associated with the 5-year survival rates was 101 (Fig. 7). The T1 GNRI

180 indicated nutritional risk in 39 out of 113 (34.5%) patients. There was a significant difference in the

181 5-year survival rates between patients with and without an increased nutritional risk (Fig. 8).

182 Figure 7. Receiver operating characteristic curve for geriatric nutritional risk index values at the

183 baseline and after a 5-year survival

184 Figure 8. Five-year survival rates, stratified by the geriatric nutritional risk index categories (low

185 nutrition: <98)

186

## 187 **Discussion**

188 This study examined the association between the baseline clinical characteristics and 5-year survival

189 rates in patients undergoing allo-HSCT. The overall 5-year survival rate was 65% (mean survival

190 period: 322 days [46–1,756 days]). The survival rates in patients with AML, ALL, CML, and ATL  
191 were 36%, 18%, 3% and 3%, respectively, and in those with MM, ML, MDS, and AA were 25%,  
192 67%, 61%, and 100%, respectively. The overall cancer-related and ML-related, leukemia-related, and  
193 MM-related survival rates were similar to, higher than, and lower than the corresponding previously  
194 reported rates in Japan [2]. Pre-treatment types and HLA matching did not affect the survival rates. In  
195 addition, the survival rates were the highest in patients undergoing UR-BMT, followed by in those  
196 undergoing allo-PBSCT and CBT. This finding is consistent with that of a previous study [16] and  
197 suggests that declining birth rates in Japan may affect donor matching for SCC [17].  
198 In the present study, BMI affected the survival rates at a cut-off value of 20.5 kg/m<sup>2</sup>, which may be a



199 useful reference for nutritional interventions during remission induction therapy or consolidation

200 therapy before allo-HSCT. A significant difference in the 5-year survival rates was observed between

201 patients with low BMIs and patients with normal and high BMIs at baseline; no other associations

202 were observed. These results are consistent with those of a meta-analysis of studies on the impact of

203 BMI on allo-HSCT outcomes [18].

204 In the present study, GNRI was associated with survival outcomes at a cut-off value of 101, although

205 a previously reported cut-off value (>99) also affected 5-year survival rates. GNRI is an indicator of

206 long-term nutritional status, which may account for the observed association; however, this indicator

207 does not account for differential blood counts, such as lymphocyte levels, which are often affected by

208 hematopoietic tumors. Nevertheless, this finding is consistent with that of a previous study on the  
209 impact of BMI on survival. SMI and SMM affected survival rates in women. FM was associated with  
210 the overall survival rates; however, no sex-specific associations were observed. Although muscle and  
211 FM values were associated with survival in the present study, the mechanisms underlying these  
212 associations remain unclear; in fact, the role of the relative metabolic rate in health outcomes remains  
213 unclear. Meanwhile, HCT-CI values and GVHD rates were not associated with the survival rates in  
214 the present study, suggesting that other pre-treatment and transplant factors may be relevant.

215 Although the T1 PS was 0 in all cases, sarcopenia was confirmed in 41.5% of the patients at T1. To  
216 increase the likelihood of a successful allo-HSCT, remission induction therapy and consolidation

217 therapy are used as pre-treatments to reduce the tumor size [5]. In this context, the present results may

218 reflect the limited activities of daily living that patients undergoing pre-treatment may engage in,

219 which may increase the risk of sarcopenia; this in turn warrants a nutritional intervention.

220 In the present study, the baseline BMI and GNRI (both of which depend on body weight) affected

221 survival outcomes of patients undergoing allo-HSCT. The impact of sarcopenia on transplantation

222 outcomes suggests a need for nutritional assessments and interventions before allo-HSCT.

223 This study has some limitations, including the lack of stratification by diagnosis and treatment type

224 and a lack of baseline BIA data (which may have biased the present findings).

225 In conclusion, the baseline BMI and GNRI values (both of which are associated with body weight),

226 affected the survival outcomes after allo-HSCT, independently of other clinical characteristics. The

227 presence of sarcopenia in patients referred for allo-HSCT suggests a need for nutritional intervention

228 as a part of pre-treatment protocols.

229

## 230 **Acknowledgements**

231 We would like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing.

232 The author would like to thank all dieticians registered at the Shizuoka Cancer Center, Japan, for their

233 assistance with data collection.

234

235

236

237 **References**

- 238 1. Sasazuki S, Inoue M, Tsuji I, Sugawara Y, Tamakoshi A, Matsuo K, et al. Body mass index  
239 and mortality from all causes and major causes in Japanese: results of a pooled analysis of 7  
240 large-scale cohort studies. *J Epidemiol.* 2011;21: 417-430. doi: [10.2188/jea.je20100180](https://doi.org/10.2188/jea.je20100180).
- 241 2. Cancer statistics in Japan. *Cancer Mortal Vital Stat Jpn.* 1958-2019. [Cite; 2021]. Available  
242 from: [https://ganjoho.jp/reg\\_stat/statistics/data/dl/en.html](https://ganjoho.jp/reg_stat/statistics/data/dl/en.html).
- 243 3. Tamaki M, Nakasone H, Nakamura Y, Kawamura M, Kawamura S, Takeshita J, et al. Body

244 weight loss before allogeneic hematopoietic stem cell transplantation predicts survival

245 outcomes in acute leukemia patients. *Transplant Cell Ther.* 2021;27: 340.e1-340.e6. doi:

246 [10.1016/j.jtct.2021.01.006](https://doi.org/10.1016/j.jtct.2021.01.006).

247 4. Aoyama T, Imataki O, Mori K, Yoshitsugu K, Fukaya M, Okamura I, et al. Nutritional risk in

248 allogeneic stem cell transplantation: rationale for a tailored nutritional pathway. *Ann Hematol.*

249 2017;96: 617-625. doi: [10.1007/s00277-016-2910-9](https://doi.org/10.1007/s00277-016-2910-9).

250 5. Japan Society for Hematopoietic Stem Cell Transplantation. Hematopoietic cell transplant

251 society guidelines. [Cited 14 June 2021]. Available from:

252 [https://www.jshct.com/modules/en/index.php?content\\_id=1](https://www.jshct.com/modules/en/index.php?content_id=1).

- 253 6. Achamrah N, Colange G, Delay J, Rimbart A, Folope V, Petit A, et al. Comparison of body  
254 composition assessment by DXA and BIA according to the body mass index: a retrospective  
255 study on 3655 measures. PLOS ONE. 2018;13: e0200465. doi: [10.1371/journal.pone.0200465](https://doi.org/10.1371/journal.pone.0200465).
- 256 7. Jia S, Qiao R, Xiao Y, Qin D, Zhao W, Zhao Y, et al. Prognostic value of sarcopenia in  
257 survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: a  
258 systematic review and meta-analysis. Support Care Cancer. 2020;28: 3533-3542. doi:  
259 [10.1007/s00520-020-05359-3](https://doi.org/10.1007/s00520-020-05359-3).
- 260 8. Sakatoku K, Ito A, Tajima K, Yamaguchi K, Kuno M, Aoki N, et al. Prognostic significance of  
261 low pre-transplant skeletal muscle mass on survival outcomes in patients undergoing

- 262 hematopoietic stem cell transplantation. Int J Hematol. 2020;111: 267-277. doi:
- 263 [10.1007/s12185-019-02773-0](https://doi.org/10.1007/s12185-019-02773-0).
- 264 9. de Souza A, Campos DJ, Schieferdecker MEM, Funke VAM, Vilela RM. Phase angle as a
- 265 screening tool for mortality risk among hematopoietic stem cell transplanted adult patients. Clin
- 266 Nutr ESPEN. 2019;29: 65-71. doi: [10.1016/j.clnesp.2018.12.004](https://doi.org/10.1016/j.clnesp.2018.12.004).
- 267 10. Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric
- 268 nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin
- 269 Nutr. 2005;82: 777-783. doi: [10.1093/ajcn/82.4.777](https://doi.org/10.1093/ajcn/82.4.777).
- 270 11. Khalil MMI, Lipton JH, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, et al. Impact of



271 comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the

272 outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. Eur J Haematol.

273 2018;100: 198-205. doi: [10.1111/ejh.13000](https://doi.org/10.1111/ejh.13000).

274 12. BMI classification. [Cited 14 June 2021]. Available from:

275 <https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body>

276 [-mass-index-bmi?source=post\\_page](https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi?source=post_page). World Health Organization.

277 13. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working

278 Group for Sarcopenia: 2019 Consensus update on sarcopenia diagnosis and treatment. J Am

279 Med Dir Assoc. 2020;21: 300–307.e2. doi: [10.1016/j.jamda.2019.12.012](https://doi.org/10.1016/j.jamda.2019.12.012).

280 14. Cunningham JJ. Body composition as a determinant of energy expenditure: a synthetic review

281 and a proposed general prediction equation. Am J Clin Nutr. 1991;54: 963-969. doi:

282 [10.1093/ajcn/54.6.963](https://doi.org/10.1093/ajcn/54.6.963).

283 15. Japanese Data Center for Hematopoietic Cell Transplantation. [Cited 14 June 2021]. Available

284 from: <http://www.jdchct.or.jp/en/outline/>

285 16. Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, et al.

286 Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone

287 marrow transplantation in adult patients with acute leukemia. Blood. 2009;113: 1631-1638. doi:

288 [10.1182/blood-2008-03-147041](https://doi.org/10.1182/blood-2008-03-147041).

- 289 17. Japanese Data Center for Hematopoietic Cell Transplantation. Activities and outcomes of  
290 hematopoietic cell transplantation in Japan; 2019. [Cited 14 June 2021]. Available from:  
291 <http://www.jdchct.or.jp/en/data/slide/2019/>.
- 292 18. Ren G, Cai W, Wang L, Huang J, Yi S, Lu L, et al. Impact of body mass index at different  
293 transplantation stages on postoperative outcomes in patients with hematological malignancies: a  
294 meta-analysis. Bone Marrow Transplant. 2018;53: 708-721. doi: [10.1038/s41409-018-0234-1](https://doi.org/10.1038/s41409-018-0234-1).

